Faeth Therapeutics (FTH) Preferred Stock Liabilities (2020)

Faeth Therapeutics' (FTH) quarterly Preferred Stock Liabilities came in at $10.9 million in Q4 2020.

Faeth Therapeutics (FTH) Preferred Stock Liabilities (2020) Analysis & Trends

Faeth Therapeutics (FTH) has 1 years of Preferred Stock Liabilities data on file, last reported at $10.9 million in Q4 2020.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $10.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $10.9 million (changed N/A YoY) and the FY2020 annual result came in at $10.9 million, changed N/A from the prior year.
Preferred Stock Liabilities steadied at $10.9 million in Q4 2020.
In the past five years, Preferred Stock Liabilities ranged from a high of $10.9 million in Q4 2020 to a low of $10.9 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.40 Bn	131.55 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.53 Bn	78.54 Bn	3.93 Bn	-
3	Argenx Se	65.20 Bn	60.02 Bn	1.37 Bn	-
4	Moderna	60.40 Bn	55.26 Bn	52.00 Mn	-
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.36 Bn	28.05 Bn	992.69 Mn	-
7	BioNTech SE	28.74 Bn	10.34 Bn	668.28 Mn	-
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn	-
9	Royalty Pharma	27.17 Bn	26.33 Bn	-	-
10	Faeth Therapeutics	179.57 Mn	179.57 Mn	-	-

Download Data

Date	Value
Dec 31, 2020	10.93 Mn